/ /

Cholesterol Disorders Year in Review

ECG Challenge: It's the Level of the Block that CountsThis 83-year-old man is treated only for hypertension and says he "feels like Tarzan." The routine ECG says otherwise.
5 Stubborn Statin Myths vs Data that Refute ThemAt AHA.17, Dr Rory Collins offered large-scale trial data to help dispel dangerous disinformation still circulating about the effects of statins.
2017 ACC/AHA Hypertension Guidelines: Case StudyClick through this short case study for an illustration of the key principles put forth in the revised ACC/AHA guidelines on hypertension diagnosis and management.
Evolocumab Impact Significant in Patients with PADLowering LDL-C levels in FOURIER trial patients with PAD had a significant impact on both MACE and MALE.
No Difference in CV Outcomes with Statin plus Add-on vs Statin AloneThe HIJ-PROPER study found intensive LDL-lowering therapy added no additional therapeutic value in patients with ACS.
How Dangerous is Digoxin in AF?Results of a post-hoc analysis of the ENGAGE-AF TIMI 48 trial show the answer could depend on a heart failure Dx.
FOURIER Clinical Outcomes Trial Results: Center Stage at ACC.17Highly anticipated, the 2-year results support the promise of PCSK9 inhibitors and also highlight important questions.
Impact of High-dose Statin on Plaque MorphologyStatins are clinically proven to improve CV outcomes--a new study offers insight into the mechanisms at work on arterial plaque.
Food Choices in Youth May Determine CV Health Come Midlife
Patient Risk Factors for Carotid RevascularizationThe Cardiovascular Health Study identifies patient factors that can be modified to stem risk for CEA.